MOR promotes self-renewal of liver cancer stem cells: a mechanism study

circZNF169 promotes self-renewal of liver cancer stem cells through regulating µ opioid receptor: a mechanism study

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100044926

Enrollment

Unknown

Registered

2021-03-31

Start date

2021-05-06

Completion date

Unknown

Last updated

2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

para-carcinoma tissue group:None

TNM stage 1 group:None

TNM stage 2 group:None

TNM stage 3 group:None

TNM stage 4 group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients admitted to hospital were diagnosed as hepatocellular carcinoma and had no immune system diseases, no history of hormone use, and no co-infection during preoperative examination; 2.Patients who have not undergone radiotherapy, chemotherapy, or immunotherapy before surgery, and intraoperative frozen sections suggest hepatocellular carcinoma.

Exclusion criteria

Exclusion criteria: 1.Patients with recent history of infection; 2.Suffering from mental illness; 3.Patients who do not cooperate with the study.

Design outcomes

Primary

Measure	Time frame
MOR expression;circZNF169 expression quantity;Lifetime;	—

Countries

China

Contacts

Public ContactLi Yi

Peking University Third Hospital

liyicomeon@163.com+86 15210903101

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026